Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications
The introduction of DPP-4 inhibitors substantially increased therapeutic options for type 2 diabetes mellitus (T2DM). The unique mechanism of action allows using these agents both as monotherapy and in combination with conventional anti-diabetes drugs. Evidence base for efficacy and safety of DPP-4...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2014-03-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/6303 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849729818725187584 |
|---|---|
| author | Elena Valer'evna Biryukova |
| author_facet | Elena Valer'evna Biryukova |
| author_sort | Elena Valer'evna Biryukova |
| collection | DOAJ |
| description | The introduction of DPP-4 inhibitors substantially increased therapeutic options for type 2 diabetes mellitus (T2DM). The unique mechanism of action allows using these agents both as monotherapy and in combination with conventional anti-diabetes drugs. Evidence base for efficacy and safety of DPP-4 inhibitors deepens every year, but to date only a few studies addressed direct comparison between individual agents within this pharmacological class. Current article presents data from the studies comparing vildagliptin with other DPP-4 inhibitors, as well as GLP-1 agonists. |
| format | Article |
| id | doaj-art-8c30a6a6702c497f943e2333951c8c6a |
| institution | DOAJ |
| issn | 2072-0351 2072-0378 |
| language | English |
| publishDate | 2014-03-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Сахарный диабет |
| spelling | doaj-art-8c30a6a6702c497f943e2333951c8c6a2025-08-20T03:09:04ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782014-03-01171818410.14341/DM2014181-846314Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medicationsElena Valer'evna Biryukova0Moscow State University of Medicine and Dentistry, MoscowThe introduction of DPP-4 inhibitors substantially increased therapeutic options for type 2 diabetes mellitus (T2DM). The unique mechanism of action allows using these agents both as monotherapy and in combination with conventional anti-diabetes drugs. Evidence base for efficacy and safety of DPP-4 inhibitors deepens every year, but to date only a few studies addressed direct comparison between individual agents within this pharmacological class. Current article presents data from the studies comparing vildagliptin with other DPP-4 inhibitors, as well as GLP-1 agonists.https://www.dia-endojournals.ru/jour/article/view/6303diabetes mellitusdpp-4 inhibitorsincretinsvildagliptin |
| spellingShingle | Elena Valer'evna Biryukova Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications Сахарный диабет diabetes mellitus dpp-4 inhibitors incretins vildagliptin |
| title | Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications |
| title_full | Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications |
| title_fullStr | Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications |
| title_full_unstemmed | Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications |
| title_short | Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications |
| title_sort | clinical implementetion of vildagliptin data from recent studies comparing incretin based medications |
| topic | diabetes mellitus dpp-4 inhibitors incretins vildagliptin |
| url | https://www.dia-endojournals.ru/jour/article/view/6303 |
| work_keys_str_mv | AT elenavalerevnabiryukova clinicalimplementetionofvildagliptindatafromrecentstudiescomparingincretinbasedmedications |